What NICE's tirzepatide recommendation means for your weight loss

You've read the headline, here's what the NICE criteria actually say

Picture this: you've seen the news coverage, checked your BMI, and you broadly fit the profile. But when you dig into TA1026, the language is dense. The recommendation applies to adults with a BMI of 35 or above, alongside at least one weight-related comorbidity from a defined list, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, those BMI thresholds are each reduced by 2.5 kg/m², in line with UK guidance on how BMI relates to health risk across different ethnicities.

NICE also specifies a review point: if someone loses less than 5% of their starting weight after six months at the highest dose they can tolerate, the prescriber should reconsider whether continuing is appropriate. Treatment is intended to run alongside a reduced-calorie diet and increased physical activity, the medicine works best as part of a wider approach, not instead of one. You can read the full detail on what NICE says about Mounjaro, or go directly to chapter 1 of NICE TA1026 if you want the exact wording.

One detail that often gets missed: NICE's recommendation covers the NHS route specifically. Private prescribers follow the licensed eligibility criteria in the Mounjaro SmPC, which allows treatment from a BMI of 27 upwards when a weight-related condition is present. The NICE threshold and the licensed threshold are not the same thing. A clinician reviewing you privately works to the licence, not the NICE commissioning criteria.

Why the NHS rollout is slower than many people expected

NICE approved tirzepatide in December 2024, but that did not mean GP surgeries started prescribing it in January 2025. NHS England set a phased rollout based on clinical priority: from June 2025, access opened to adults with a BMI of 40 or above with four or more of the five qualifying conditions. The second cohort (BMI 35 to 39.9 with four or more conditions) became eligible from around June 2026. A further expansion, covering BMI 40 or above with three conditions, is planned for around March 2027.

If you have been waiting to see where you fall in this schedule, it can feel like the goalposts keep moving. The rollout is structured this way to manage demand and prioritise the highest clinical need first, which is a reasonable NHS position, though a frustrating one if you sit in a cohort that opens later. From 1 April 2026 GP practices can prescribe under the updated GP contract, but participation varies, your surgery may not be taking part yet.

People who meet the clinical criteria but cannot access tirzepatide through the NHS, or do not want to wait, often look at Mounjaro for weight loss through a regulated private pharmacy instead. That is a legitimate route; the key is ensuring the pharmacy is GPhC-registered and that a real clinician reviews your case before anything is prescribed.

What the trial evidence behind the NICE decision actually showed

NICE does not approve a medicine on the basis of a press release. The recommendation drew heavily on the SURMOUNT-1 trial, published in the New England Journal of Medicine, which enrolled 2,539 adults with obesity and followed them for 72 weeks. At the highest 15mg dose, participants achieved an average body-weight reduction of around 20 to 21%. The SURMOUNT-5 trial, published in 2025, then compared tirzepatide directly with semaglutide 2.4mg in a head-to-head design and found tirzepatide produced greater average weight loss over the same period.

NICE's appraisal committee reviewed this evidence alongside cost-effectiveness modelling before issuing its recommendation. The committee also noted that indirect comparisons across the GLP-1 class favour tirzepatide, while acknowledging that the field is still developing. If you want more background on how tirzepatide is used for weight loss, including how the trial results translate into real-world expectations, there is more detail on that page.

It is worth keeping in mind that trial results reflect averages across a large group under controlled conditions. Individual responses vary; a prescriber cannot predict exactly what you will lose, and no clinic should tell you otherwise. The medicine is also a Black Triangle (▼) product in the UK, meaning it is subject to additional MHRA monitoring as post-market safety data continues to accumulate.

Choosing between the NHS and a private prescription

The honest answer is that these are different paths with different trade-offs, not one clearly right and one clearly wrong. The NHS route is free at the point of use but requires meeting the phased rollout criteria and, in most cases, waiting. If your BMI and conditions place you in a later cohort, that wait could be a year or more from today, and that assumes your GP practice has opted into the new prescribing arrangements.

A private route through a GPhC-registered pharmacy means no waiting list and no referral. It does cost money, and you should factor that into your thinking. Our tirzepatide page covers cost context alongside clinical considerations, which is worth reading if you are weighing up your options. The important safeguard either way is clinical assessment by a real prescriber before any medicine is dispensed. You can verify any online pharmacy on the GPhC pharmacy register in about thirty seconds, it matters.

If payday timing, a bank holiday, or a Monday order sits in the back of your mind as a practical consideration, those details are worth checking directly with whichever service you choose, so expectations are clear from the start. At nume, our pharmacy and clinical team handle consultations with same-day review on working days. If you have questions before starting, the FAQs page covers the most common ones, or you can get in touch directly. When you are ready to take the next step, start your free consultation here.